

4th edition

Unmet challenges in high risk hematological malignancies: from benchside to clinical practice

Turin, March 26-27, 2026

Starhotels Majestic

Scientific board:

Marco Ladetto (Alessandria)

Umberto Vitolo (Candiolo -TO)



AUSPICES

Azienda Ospedaliero-Universitaria di ALESSANDRIA SS Antonio e Biagio e Cesare Arrigo

FIL - Fondazione Italiana Linfomi

GIMEMA - Gruppo Italiano Malattie EMatologiche dell’Adulto

GITMO - Gruppo Italiano per il Trapianto di Midollo Osseo, cellule staminali emopoietiche e terapia cellulare

ISTITUTO DI CANDIOLO - Fondazione del Piemonte per l’Oncologia - IRCCS

RETE ONCOLOGICA DEL PIEMONTE E DELLA VALLE D’AOSTA

SIE - Società Italiana di Ematologia

SIES - Società Italiana di Ematologia Sperimentale

UNIVERSITÀ DEL PIEMONTE ORIENTALE

UNIVERSITÀ DI TORINO

FACULTY

Othman Ernesta Igor Monica Peter Sara Monika Benedetto Christian Annalisa Daniela Annarita Charlie Elena Antonio Mattia Alice Andres J.M. Robin Gianluca Guido Nicola Katharina Maria Mats Wojciech Maria Josè Marco	Al-Sawaf Audisio Aurer Balzarotti Borchmann Bringhen Brueggemann Bruno Buske Chiappella Cilloni Conconi Craddock Crisà Cuneo D’Agostino Di Rocco Ferreri Foà Gaidano Gini Goekbuget Goetze Gomes da Silva Jerkeman Jurczak Kersten Ladetto	Cologne, Germany Torino, Italy Zagreb, Croatia Rozzano-MI, Italy Cologne, Germany Cuneo, Italy Kiel, Germany Torino, Italy Ulm, Germany Milano, Italy Torino, Italy Biella, Italy Birmingham, United Kingdom Candiolo-TO, Italy Ferrara, Italy Torino, Italy Roma, Italy Milano, Italy Roma, Italy Novara, Italy Ancona, Italy Frankfurt, Germany Munich, Germany Lisboa, Portugal Lund, Sweden Kraków, Poland Amsterdam, The Netherlands Alessandria, Italy	Georg Stefano Maurizio Massimo Priyanka Jessica Stefania Raffaele Adela Daniela Christiane Karthik Alessandro Umberto Luigi Davide Chiara Giuseppe Gilles Valeria Cyrille Marek David Adriano Carlo Umberto Francesco Pier Luigi	Lenz Luminari Martelli Massaia Metha Okosun Oliva Palmieri Perolla Pietrasanta Pott Ramasamy Rambaldi Ricardi Rigacci Rossi Rusconi Saglio Salles Santini Touzeau Trneny Valcarcel Venditti Visco Vitolo Zaja Zinzani	Münster, Germany Reggio Emilia, Italy Roma, Italy Torino, Italy Bristol, United Kingdom London, United Kingdom Torino, Italy Roma, Italy Tirane, Albania Alessandria, Italy Kiel, Germany Oxford, United Kingdom Bergamo, Italy Torino, Italy Roma, Italy Bellinzona, Switzerland Milano, Italy Orbassano-TO, Italy New York, USA Firenze, Italy Nantes, France Praha, Czech Republic Barcelona, Spain Roma, Italy Verona, Italy Candiolo-TO, Italy Trieste, Italy Bologna, Italy
---	---	---	---	--	--

09.15 **Welcome and introduction**

M. Ladetto, U. Vitolo and Scientific Authorities

SESSION 1: LARGE B-CELL LYMPHOMA

Chairmen: A. Di Rocco, F. Zaja

09.45 **DEBATE - Molecularly driven vs agnostic treatment strategies in first line DLBCL**

G. Lenz vs M. Gomes da Silva

10.25 **The evolving landscape in R/R DLBCL: bispecifics, ADC and novel engineered antibodies**

M. Trneny

10.45 **CNS prophylaxis: an old chap or a still valid option?**

A.J.M. Ferreri

11.05 **Panel discussion**

**SESSION 2: HODGKIN LYMPHOMA
AND T-CELL LYMPHOMA**

Chairmen: L. Rigacci, C. Rusconi

11.15 **DEBATE - Minimizing toxicity and preserving efficacy in early-stage Hodgkin lymphoma:**

- the radiation oncology perspective
- the chemoimmunotherapy perspective

U. Ricardi

I. Aurer

11.55 **DEBATE - Immunochemotherapy-based strategies for sparing toxicity and improving efficacy in advanced-stage Hodgkin lymphoma:**

- Beacopp-based
- AVD-based

P. Borchmann

P.L. Zinzani

12.35 **How I treat high risk T-cell lymphomas**

A. Chiappella

12.55 **Lunch**

13.45 **LECTURE I**

Chairman: U. Vitolo

The paradigm shift in the treatment of follicular lymphoma from chemoimmunotherapy to chemo-free approaches with bispecifics, novel engineered antibodies, and small molecules

G. Salles

SESSION 3: INDOLENT LYMPHOMA

Chairmen: **A. Conconi, G. Gini**

- 14.15 Biology of high-risk indolent lymphoma
J. Okosun
- 14.35 First line treatment in high-risk follicular lymphoma
S. Luminari
- 14.55 Waldenström macroglobulinemia: from chemoimmunotherapy
to chemo-free approaches
C. Buske
- 15.15 Panel discussion

SESSION 4: MANTLE CELL LYMPHOMA

Chairmen: **M. Balzarotti, M. Martelli**

- 15.25 How MRD detection is changing in the era of BTKi in MCL
C. Pott
- 15.45 The role of BTK inhibitors in first line MCL therapy
M. Jerkeman

- 16.05 Chemo-free approaches in relapsed/refractory
mantle cell lymphoma
C. Visco

- 16.25 Panel discussion

16.45 LECTURE 2

Chairman: **M. Ladetto**

Novel frontiers with CAR-T treatment in B-cell malignancies
M.J. Kersten

SESSION 5: CHRONIC LYMPHOCYTIC LEUKEMIA

Chairmen: **A. Cuneo, M. Massaia**

- 17.15 Biology of high risk CLL and acquired resistance
D. Rossi
- 17.35 Role of combination treatment in first line
O. Al-Sawaf
- 17.55 How I treat BTKi failures
W. Jurczak
- 18.15 Panel discussion

SESSION 6: MULTIPLE MYELOMA

Chairmen: *S. Brighen, B. Bruno*

- 08.30 Static and dynamic prognostic factors in multiple myeloma: roles of disease biology and MRD
S. Oliva
- 08.50 DEBATE - CAR-T vs bispecific antibodies: real roles in real life
- CAR-T *M. D'Agostino*
- Bispecifics *K. Ramasamy*
- 09.30 New clinical trails: integration of new therapies (bispecific antibodies, antibodies drug-conjugated and CAR-T) and MRD
C. Touzeau
- 09.50 Panel discussion

SESSION 7: MYELODISPLASTIC SYNDROME

Chairmen: *D. Cilloni, V. Santini*

- 10.00 DEBATE - TP53-mutated MDS: is transplant the only way?
- Yes *D. Valcarcel*
- No *K. Goetze*

- 10.40 Symptomatic anemia in MDS: when and how to treat
E. Crisà
- 11.00 Panel discussion

SESSION 8: ACCESS DISPARITY TO NOVEL TREATMENTS AS A NOVEL "HIGH RISK"

Chairmen: *R. Foà, G. Gaidano*

- 11.10 Current situation and how to foster access in medium income countries
A. Perolla
- 11.30 The role of international societies in promoting worldwide access to modern diagnosis and treatment
G. Gaidano
- 11.50 Panel discussion
- 12.00 *Lunch*

SESSION 9: ACUTE LYMPHOBLASTIC LEUKEMIA

Chairmen: *E. Audisio, D. Pietrasanta*

- 13.00 Biology of high risk ALL
M. Brueggemann
- 13.20 The evolving strategies in the treatment of young adults and elderly patients with acute lymphoblastic leukemia
A. Rambaldi
- 13.40 Allogeneic transplant and CAR-T in adult ALL: which comes first?
N. Goekbuget
- 14.00 Panel discussion

SESSION 10: ACUTE MYELOBLASTIC LEUKEMIA

Chairmen: *G. Saglio, A. Venditti*

- 14.10 Biologic features of HR-AML
R. Palmieri
- 14.30 High risk AML: how to incorporate new drugs into the treatment of AML
P. Metha
- 14.50 Allogeneic stem cell transplant in HR-AML
C. Craddock
- 15.10 Panel discussion
- 15.20 **Closing remarks**
M. Ladetto, U. Vitolo

With an unrestricted educational grant of:

abbvie

Johnson & Johnson



GENERAL INFORMATION

REGISTRATION

Registration is available at www.ercongressi.it - section "I nostri congressi/anno 2026"
The registration fee includes: conference kit, participation in the scientific sessions, certificate of attendance, coffee break, lunch, slides of the meeting.

MEETING VENUE

Starhotels Majestic

Corso Vittorio Emanuele II, 54
10123 Torino, Italy
Tel. +39 011 539153

ITALIAN CME CREDITS

An Italian CME application has been submitted as follows:

Provider Studio ER Congressi SRL: ID 828-468566.

No. 9,8 CME credits for Physicians (Haematology, Oncology, Internal Medicine, Radiotherapy), Pharmacists (public pharmacist of the National Health Service), Nurses and Biologists.

Educational objective: linee guida-protocolli-procedure.

OFFICIAL LANGUAGE

English

BADGE AND CERTIFICATE OF ATTENDANCE

All registered participants and speakers will be given a badge which must be worn in order to be admitted to the scientific sessions.

A certificate will be given to all participants at the end of the meeting.

SCIENTIFIC BOARD

Marco Ladetto MD

Associate Professor in Haematology
University of Eastern Piedmont Amedeo Avogadro
S.S. Antonio and Biagio and Cesaro Arrigo Hospital
Via Venezia, 16 - 15121 Alessandria, Italy

Umberto Vitolo MD

Hematology Consultant
Candiolo Cancer Institute - FPO-IRCCS
Strada Provinciale, 142 - 10060 Candiolo (TO), Italy

SCIENTIFIC COMMITTEE

Prof. Benedetto Bruno - Torino

Prof. Gianluca Gaidano - Novara

Prof.ssa Valeria Santini - Firenze

Prof. Adriano Venditti - Roma

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti, 1/7 - 40124 Bologna, Italy
Phone +39 051 4210559
E-mail: ercongressi@ercongressi.it
www.ercongressi.it

ER Congressi

